Nektar Therapeutics (NKTR) Stock Analysis
Verdict: AVOID
Deteriorating cash reserves and heavy insider selling outweigh clinical potential; current burn suggests a liquidity crisis within 12 months.
Investment score: 38/100
Analysis as of
Is Nektar Therapeutics stock worth reviewing? AI model thesis
The AI model views NKTR as a high-risk speculative vehicle facing imminent dilution or liquidity threats due to a massive FCF shortfall.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Nektar Therapeutics opportunities and risks
What speaks for NKTR
- Phase 3 Data Catalysts
What speaks against NKTR
- Imminent Liquidity Crisis
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NKTR | n/a | 25.0x | n/a | 99.4% | -284.2% | -14.7% |
| TARS | n/a | 5.3x | n/a | 90.4% | -9.0% | -1.1% |
| SUPN | n/a | 3.6x | 51.1x | 89.4% | -3.7% | 2.9% |
| MBX | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.1% |
| TRVI | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.3% |
| AMRX | 45.3x | 1.8x | 12.7x | 38.7% | 4.0% | 3.7% |
| Peer median | n/a | 1.8x | n/a | 38.7% | 0.0% | -1.1% |
Frequently asked questions about Nektar Therapeutics (NKTR)
Is NKTR stock a good investment?
The cached TradeMates AI model rates Nektar Therapeutics as AVOID with an investment score of 38/100. The AI model views NKTR as a high-risk speculative vehicle facing imminent dilution or liquidity threats due to a massive FCF shortfall. This is algorithmic model output, not personal investment advice.
Is NKTR stock a buy?
The TradeMates model verdict for NKTR is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.